France · 
What does KurmaPartners invest in?
KurmaPartners invests most often at Series A and Seed (53% of the rounds on record), in sectors such as Healthcare and Biotechnology.
KurmaPartners highlights
- 01
10 cheques in the last 12 months
- 02
Mostly Series A and Seed: 53% of its rounds
- 03
Sole investor in 3 rounds, median $6.8M
What they do
"Major player in the funding of healthcare and biotechnology in Europe" and "We invest at various stages of maturity, from company creation to capital expansion"From their own website
- Type
- VC firm
- Cheque size
- $100K – $5.0M as they say
- Stages
- Pre-seedSeedSeries ASeries BGrowth
- Sectors
- HealthcareBiotechnology
- Based in
- Paris, France
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first69 appearances
- 2026
8 rounds
- Oct
- May
- Apr
- Apr
- Mar
- Feb
- Feb
- Jan
- 2025
17 rounds
- Dec
- Nov
- Oct
- Sept
- Sept
- Jul
- Jul
- Jul
- Jun
- Jun
- May
- Apr
- Apr
- Apr
- Apr
- Jan
- Jan
- 2024
15 rounds
- Dec
- Dec
- Nov
- Sept
- Aug
- Jul
- Jul
- Jul
- Jun
- Jun
- Jun
- May
- Mar
- Feb
- Feb
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
We hold 16 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
Who backs their funds
3 LPs on record in KurmaPartners's funds
- Funds
- 1
The institutions that put money into its funds, which the firm then invests in companies.Source: fund news.
Eurazeo1 fundFund Vintage Committed Kurma Partners Biofund IV - - 
Bpifrance1 fundFund Vintage Committed Kurma Partners Biofund IV - - 
CSL1 fundFund Vintage Committed Kurma Partners Biofund IV - -
What they claim to have backed
From their own portfolio page (on their website)
40 of 52 we have independently watched raise
Am-pharmaAmolytpharmaArkhnAsceneuronAurismedicalAvidicureAxithraBioserenityBlinkbiomedicalCardiologsDamaemedicalDnascriptElkedoniaEvlabioGanymedroboticsHopiaImchecktherapeuticsIobiotechLaigobioMedincellMedlumicsMemo-therapeuticsNaox-technologiesNuclidiumNuevocorOmnidocPathoquestPharvarisPoppinsRaidiumSafeorthopaedicsScirhomSensomeShorlaoncologySmartcatchStep-phStillatechnologiesVivet-therapeuticsXeltisZealandpharmaAlveuspharmaArgobiostudioByondCharlesCorteriapharmaGermitecHellosunrisePantera-lifeRcptRycarmaStrategic-partnersSynendos
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.